Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its Nav1.8 inhibitors, which are being developed as non-opioid treatments for pain.
This funding will also support the progression of the company’s wider pipeline of therapies.
The financing round was spearheaded by Blue Owl Capital-managed fund. Other contributors included Sanofi Ventures, Deep Track Capital, Qatar Investment Authority and Cormorant Asset Management.
Foresite Capital, 5AM Ventures, Alexandria Venture Investments and Westlake Village BioPartners also supported the company’s goal of developing safer pain management solutions.
Latigo Biotherapeutics CEO Nima Farzan stated: “The need for non-opioid pain treatments has never been more urgent, and this financing allows us to accelerate the development of our robust portfolio of pain medicines that have the potential to transform the treatment landscape.
“We appreciate the support of our new and existing investors as we work to bring best-in-class, non-addictive pain treatments to patients.”
The company has recently shared encouraging Phase I outcomes for its orally administered lead candidate, LTG-001, for non-opioid pain relief.
This selective Nav1.8 inhibitor is aimed at addressing acute pain at its root cause. The initial human trial data indicated that this therapy was well-tolerated and quickly absorbed.
Another company’s candidate, LTG-305, is also an oral, selective Nav1.8 inhibitor and is currently undergoing a Phase I trial. It is a potential non-opioid therapy for chronic pain.
Latigo develops non-opioid pain medications that directly target the source of pain. Its mission is to offer rapid-acting pain relief without addiction risks.
In early March 2025, the company announced the receipt of fast track designation for LTG-001 from the US Food and Drug Administration for acute pain treatment.
LTG-001 operates by inhibiting peripheral sensory neurons that are responsible for sending pain signals, thereby eliminating these signals from reaching the central nervous system.
